Regenxbio (RGNX) Change in Accured Expenses (2014 - 2025)

Regenxbio's Change in Accured Expenses history runs 12 years deep, the most recent figure standing at $45000.0 for Q4 2025.

• On a quarterly basis, Change in Accured Expenses rose 103.88% year-over-year to $45000.0 in Q4 2025; TTM through Dec 2025 was $229000.0, a 108.78% increase from a year earlier, with the FY2025 full-year figure at $229000.0, up 108.78% from the prior year.
• Change in Accured Expenses slipped to $45000.0 in Q4 2025 per RGNX's latest filing, from $3.2 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $33.5 million in Q3 2022 and bottomed at -$33.6 million in Q4 2022.
• The 5-year median for Change in Accured Expenses is $76000.0 (2023), against an average of -$1.5 million.
• Biggest YoY gain for Change in Accured Expenses was 111883.33% in 2022; the steepest drop was 11631.96% in 2022.
• Year by year, Change in Accured Expenses stood at $291000.0 in 2021, then slumped by 11631.96% to -$33.6 million in 2022, then jumped by 100.36% to $121000.0 in 2023, then slumped by 1059.5% to -$1.2 million in 2024, then jumped by 103.88% to $45000.0 in 2025.
• Per Business Quant, the three latest RGNX Change in Accured Expenses figures stand at $45000.0 (Q4 2025), $3.2 million (Q3 2025), and $11.5 million (Q2 2025).